I don’t think so. IMO this is more grass roots. This is using...

I don’t think so. IMO this is more grass roots. This is using screening of a wide range of tumour types against Zantrene single agent and Zantrene-based combinations.

IMO this will enable RAC to then build a ranked list of Zantrene efficacy for the screened cancer types.

This supports a number of things, including:

• Prioritisation of cancer subtypes when assessed in conjunction with unmet need
• Preliminary assessment of potential NPV value for each cancer subtype ( albeit with a higher discount rate as it will be preclinical )